Background: Osteoarthritis (OA) is a joint disease in which cartilage degradation is the central pathological change. In this study, we investigated the anti-osteoarthritic effects of licochalcone A (Lico A) in rat chondrocytes. Methods: Polymerase chain reaction and Western blotting were performed to evaluate the expression of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-5, ADAMTS-4, collagen II, matrix metalloproteinase (MMP)-13 and MMP-1 at both the gene and protein levels, respectively. In addition, the wnt/β-catenin and nuclear factor kappa B (NF-κB) signaling pathways were also analyzed by Western blotting. Results: Lico A downregulated ADAMTS-5, ADAMTS-4,MMP-13 and MMP-1 expression, and diminished the IL-1β-induced inhibition of collagen II. In addition, the activation of β-catenin and phosphorylation of p65 and IKKα/β were suppressed by Lico A. Conclusions: Our results suggest that Lico A inhibits MMPs and ADAMTS partly via the NF-κB and wnt/β-catenin signaling pathways in rat chondrocytes. Thus, Lico A may have therapeutic effects in OA.
Introduction
Osteoarthritis (OA) is a common joint disease that often causes pain and disability, particularly in older people [1] [2] [3] [4] . Many factors such as mechanical, biochemical, and enzymatic factors are involved in its onset [5] .However, the mechanisms underlying this disease are still unclear. As a pro-inflammatory cytokine, interleukin-1beta (IL-1β) leads to the apoptosis of chondrocytes and degradation of the extracellular matrix (ECM), which results in cartilage degeneration [6] [7] [8] . Previous studies have shown that the degeneration Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry Table 1 . Primers of targeted genes perScript™ III First-Strand Synthesis SuperMix for qRT-PCR Kit (Invitrogen) was used to reverse transcribe total RNA to complementary DNA (cDNA) following the manufacturer's instructions. The amplification of MMPs, ADAMTS, and collagen II was performed using the Power SYBR® Green PCR Master Mix kit (Applied Biosystems, Foster City, CA, USA) under conditions of 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and 60°C for 60 s [24] . To normalize expression, 18S rRNA was amplified as an internal control. The primers used are shown in Table 1 . All of the experiments were performed according to the manufacturer's protocol in triplicate using three independent samples. Quantitative real-time PCR (qPCR) data were calculated using the 2 (−ΔΔCT) method.
Western blot analysis
Cells were washed using ice-cold phosphatebuffered saline followed by addition of 40 μL RIPA buffer containing 0.4 μL protease inhibitors for 30 min to extract all of the proteins. Then the mixture was centrifuged and quantified using a BCA Protein Assay kit (Beyotime Biotechnology, Shanghai, China), and electrotransferred to nitrocellulose membranes. The membranes were incubated with Tris-buffered saline with tween (TBS-T) for 1 h and cut into sections based on protein molecular weights. Then the membranes were incubated with primary antibodies against ADAMTS-5, ADAMTS-4, collagen II, MMP-13, MMP-1, β-ctenin, β-actin, (Santa Cruz Biotech, Inc., Dallas, TX, USA), IκB alpha, p-IKK alpha/beta, IKK alpha/beta, p-65, and p-p65 (Abcam Inc., Cambridge, UK) for 12 h at 4°C. After washing with TBS-T, the membranes were incubated with secondary antibodies (Thermo Fisher, Waltham, MA, USA) at 25°C for 1 h. The membranes were washed again with TBS-T, and immunoreactive bands were detected by enhanced chemiluminescence (Thermo Fisher) and exposure to X-ray film (Kodak, Hangzhou, China) for densitometry analysis (BandScan 5.0 sofware). All of the assays were performed in triplicate.
Statistical analysis
All data are expressed as the mean ± SD. Data were analyzed using one-way ANOVA. Dunnett's test was used as the post-test for ANOVA. Differences were considered statistically significant when P<0.05 (*) or P < 0.01 (**).
Results

Effects of Lico A on chondrocyte viability
MTT assays revealed that Lico A had no cytotoxicity at a concentration of 10 μM (Fig.1) 
Effects of Lico A on ADAMTS-5, ADAMTS-4, Collagen II, MMP-13 and MMP-1 expression in chondrocytes
qPCR was performed to measure the mRNA expression of ADAMTS-5, ADAMTS-4, collagen II, MMP-13, and MMP-1 in IL-1β-stimulated chondrocytes. The expression of ADAMTS-5, ADAMTS-4, MMP-13 and MMP-1 was decreased and the expression of collagen II was increased by Lico A in a dose-dependent manner (Fig. 2) . Western blot analysis revealed that the protein expression of ADAMTS-5, ADAMTS-4, collagen II, MMP-13 and MMP-1 was similar to the mRNA expression (Fig. 3) .
Effects of Lico A on NF-κB and wnt/β-catenin signaling pathways
We also investigated the effects of Lico A on both the NF-κB and wnt/β-catenin signaling pathways, and found that IL-1β activated both pathways. However, treatment with Lico A reduced the activation of both pathways, and p-IKKα, β, p-p65, and β-catenin levels were downregulated. In addition, the gene and protein expression of IκBα, an inhibitor of NF-κB, significantly increased after Lico A treatment (Fig. 4) .
Discussion
In this study, we investigated the effects of Lico A on IL-1β-stimulated chondrocytes, and found that Lico A reduced expression of ADAMTS-5, ADAMTS-4, MMP-13 and MMP-1 in rat chondrocytes. In addition, the expression of collagen II was upregulated by Lico A.
Collagen II is an important component of the ECM, and the expression of collagen II is decreased in OA. Therefore, inhibiting collagen II degradation is a strategy for OA treatment. In this study, IL-1β stimulation resulted in reduced collagen II expression. However, Lico A upregulated the expression of collagen II, which suggests that Lico A has protective effects in chondrocytes.
In OA, enzymes are secreted that degrade the ECM including ADAMTS-5, ADAMTS-4, MMP-13, and MMP-1. These enzymes can cleave collagen II and aggrecan in cartilage. Thus, downregulation of these enzymes could be beneficial to cartilage [25, 26] . In this study, stimulation of IL-1β resulted in the increased expression of ADAMTS-5, ADAMTS-4, MMP-13, and MMP-1. Lico A significantly inhibited the upregulation of ADAMTS-5, ADAMTS-4, MMP-13, and MMP-1 in chondrocytes. In addition, Lico A diminished the IL-1β-induced inhibition Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry of collagen II expression. A previous study reported that Lico A inhibits the expression of MMP-1 and MMP-3 in human lung cancer cells [22] . Our results demonstrate that Lico A has anti-catabolic properties in rat chondrocytes. The importance of the NF-κB pathway in the inflammatory process has been well established. Recently, Zhou et al. reported that by controlling the activation of NF-κB signaling, IL-1β can modulate ADAMTS expression [27] . Moreover, the critical role of NF-κB in the regulation of MMP expression has also been recognized [28, 29] .. For NF-κB activation, inhibitors of κB (IκB) are ubiquitinated after phosphorylation by IKK, which releases NF-κB dimers, after which p50 and p65 heterodimers are released [30] [31] [32] . In this study, we found that IL-1β stimulation resulted in activation of the NF-κB pathway, and that Lico A significantly suppressed the phosphorylation of IKKα/β and p65 and increased IκBα expression. These results suggest that the NF-κB pathway may be involved in the downregulation MMPs and ADAMTS by Lico A in IL-1β-stimulated chondrocytes.
The wnt/β-catenin signaling pathway is related to cartilage homeostasis and joint remodeling [33] . In addition, a previous study showed that β-catenin was overexpressed in joint tissues from OA patients and animals [7] . In this study, the expression of β-catenin was significantly downregulated by Lico A in chondrocytes. Thus, we speculated that the anticatabolic effects of Lico A may partly occur through inhibition of the wnt/β-catenin signaling pathway.
Conclusion
This study demonstrated that Lico A can inhibit IL-1β-induced ADAMTS-5, ADAMTS-4, MMP-13, and MMP-1 expression at both the gene and protein levels in rat chondrocytes. Moreover, the NF-κB and wnt/β-catenin signaling pathways may be involved in this process. Thus, Lico A may be a potential treatment for OA.
